Comparison between CELLECT BIOTECH / S (APOP) and Insulet (PODD)

Business



[ad_1]

Insulet (NASDAQ: PODD) and CELLECT BIOTECH / S (NASDAQ: APOP) are both medical companies, but what is the best deal? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, badyst recommendations, earnings and profitability.

Analyst Notes

This is a breakdown of the current ratings and recommendations for Insulet and CELLECT BIOTECH / S provided by MarketBeat.

Rating of the rating Rankings of a Hold Buy Shares Buy Ratings Strong Rating ranking
Insulet 0 [19659011] 3 13 13 1 2.88
CELLECT BIOTECH / S 0 0 1 0 3,00 [19659022Insuletcurrentlyhasaconsensustargetpriceof$9088indicatingapotentialupsideof909%CELLECTBIOTECH/Shasaconsensustargetpriceof$1400indicatingapotentialupsideof11572%GivenCELLECTBIOTECH/S'shighestconsensualratinganditshigherupsidepotentialbadystsclearlybelievethatCELLECTBIOTECH/SismorefavorablethanInsulet

Profitability

This table compares the net margins of # 39; Insulet and CELLECT BIOTECH / S on badets

Net Margins Return on Equity Return on Assets
Insulet -4.82% -20.02 % -3.60%
CELLECT BIOTECH / S [19659010] N / A -93.41% -59.62%

Earnings & Valuation

This table is the same as income, earnings per share and valuation of Insulet and CELLECT BIOTECH / S

Gross Income ] Ratio Price / Sales Net Profit Earnings per Share [19659005] Price / earnings ratio
Insulet $ 463.77 million 10.55 – $ 26.83 million ($ 0.46) [19459] 038] -181.09
CELLECT BIOTECH / S N / A N / A – $ 8.14 million ($ 1.46) -4.45 [19659054] CELLECT BIOTECH / S has lower incomes, but higher incomes than Insulet. Insulet is trading at a lower price / earnings ratio than CELLECT BIOTECH / S, which indicates that it is currently the most affordable of the two stocks.

Risk & Volatility

Insulet has a beta of 1.41, which means that its price is 41% more volatile than the S & P 500. Comparatively, CELLECT BIOTECH / S has a beta of 4.68, which means that its price is 368% more volatile than the S & P 500.

Institutional and insider ownership

6.2% of CELLECT BIOTECH / S shares are held by institutional investors . 3.6% of Insulet shares are held by insiders of the company. Strong institutional ownership is an indication that endowments, large fund managers and hedge funds believe that a stock will outperform the market in the long run

Abstract

Insulet Beats CELLECT BIOTECH / S on 7 of 13 factors compared between the two [Insolet Corporation] Insulet Corporation develops, manufactures and sells insulin delivery systems for people with insulin-dependent diabetes in the United States. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin dispensing system, Personal Diabetes Manager, a portable wireless device, and customizes the platform. Omnipod technology The company sells and markets its Omnipod system through a combination of direct sales representatives and independent. tooth distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Mbadachusetts.

About CELLECT BIOTECH / S

CELLECT BIOTECH / S logo Cellect Biotechnology Ltd., a biotechnology company, develops technologies for the functional selection of stem cells in the field of medicine regenerative and stem cell-based therapies in Israel. its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients with hematologic malignancies. The company was founded in 2011 and is based in Kfar Saba, Israel.

Receive news and reviews of Insulet Daily – Enter your email address below to receive a concise daily summary of the latest news and badyst ratings for Insulet and related companies with daily newspaper free from MarketBeat.com er.

[ad_2]
Source link

Tags

Powered by https://naaju.com/israel | Designed by Naaju
© Copyright 2024, All Rights Reserved